CompletedNCT05615948
Aspirin and ketamine added to treatment-resistant depression care
About this title
Read the official source — NCT05615948Medication studyAges 18–89United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 89 years.
- Listed locations
- BrooklynSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: December 6, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 15
- Sponsor
- Theresa Jacob, PhD, MPH
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 89 Years
- Official registry ID
- NCT05615948
- Official title
Show the full official title
An Open-Label Clinical Trial of Simultaneous Administration of Oral Aspirin and Ketamine as Adjunct to Oral Antidepressant Therapy in Treatment-Resistant Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Brooklyn
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Theresa Jacob, PhD, MPH.
Did this study involve medication?
Yes. The study involved medication, including VTS-K.
Who was this study for?
Listed age limits: 18 years to 89 years.
